Pre-Hospital Low ALT Activity, a Marker of Sarcopenia and Frailty, is Associated with Increased Long-Term Mortality after COPD Exacerbations. Historic Prospective Cohort Study.

CURRENT STATUS: UNDER REVIEW

Nir Lasman
Sheba Medical Center at Tel Hashomer

Matan Shalom
Sheba Medical Center at Tel Hashomer

Natia Turpashvili
Sheba Medical Center at Tel Hashomer

Gal Goldhaber
Sheba Medical Center at Tel Hashomer

Yulia Lifshitz
Sheba Medical Center at Tel Hashomer

Eyal Leibowitz
Yoseftal medical center

Gideon Berger
Rambam Health Care Campus

Gilat Zalzman-Shenhav
Sheba Medical Center at Tel Hashomer

Adi Brom
Sheba Medical Center at Tel Hashomer

Dor Cohen
Sheba Medical Center at Tel Hashomer

Chen Avaki
Sheba Medical Center at Tel Hashomer
Abstract
Background. COPD exacerbations have negative impact on patients' survival. Several risk factors for grave outcomes of such exacerbations have been described. Muscle dysfunction and mass loss were shown to impact negatively on prognosis and survival. Low activity of the enzyme ALT (Alanine amino-transferase) in the blood is a known indicator for sarcopenia and frailty, however, no previous studies addressed the association of low ALT amongst patients hospitalized due to COPD exacerbation and long-term survival. Methods. This is a historic prospective cohort study of patients hospitalized due to acute COPD exacerbation. Results. Included were 232 consecutive COPD exacerbation patients. The median time of follow-up was 34.9 months (IQR 23.13 – 41.73 months). During this period 104 (44.8%) patients died. All patients were grouped to quartiles according to blood ALT levels (after exclusion of cases considered to have hepatitis (ALT > 40 IU)). The risk of long-term mortality increased, in a statistically significant manner, amongst patients with low ALT values: the median survival of patients with ALT < 11 IU was 18.5 months only while the median survival for the rest of the study group was not reached. For ALT < 11IU; 12-16IU; 17-20IU and >21IU the mortality rates were 69%; 40.9%; 36.3% and 25% respectively (p < 0.001 for comparison of lower quartile with upper three quartiles). The crude hazard ratio for mortality amongst patients with ALT levels lower than 11IU was 2.37 (95% CI; 1.6 – 3.5). This increased risk of mortality remained significant after adjustment for age, weight, creatinine, albumin concentration and cardiovascular diseases (HR = 1.83; 95% CI 1.08 – 3.1, p < 0.05). Conclusions. Low ALT values, a biomarker of sarcopenia and frailty, are associated with poor long-term survival amongst patients hospitalized due to COPD exacerbation.

Background
Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease worldwide. Acute COPD exacerbations have dismal results, both in high patients' mortality (ranging in different publications from over 5% to over 18% in-hospital mortality during exacerbation (1,2)) and in extremely large health expanses (1-6). Several risk factors for grave outcomes of COPD exacerbations have been described: Sakamoto and co. (6) performed multivariable logistic regression analysis of over 3,000 COPD patients and found that older age and lower body mass index, amongst other patients'
characteristics, are significantly associated with increased risk of in-hospital mortality. Serra-Picamal and co., in a big-data analysis of 17,555 COPD patients, identified early re-hospitalizations as another risk factor for mortality after hospitalization due to COPD exacerbation (7).

Survival and COPD mortality are influenced by both dysfunction and impaired muscle mass (sarcopenia) (8,9). Additionally, COPD exacerbations also rapidly induce loss of muscle mass and function through the activation of several biological pathways and systems. Sarcopenia and frailty, two overlapping syndromes, defined as causing increased mortality and frequent hospital admissions, are prime candidates for having a negative impact on COPD exacerbations’ outcomes. In a review published back in 2005, Morley and co. (10) stated that CODP is one of the chronic diseases particularly associated with frailty. Vellas and co. (11) relate to COPD as a causative agent for decreased muscle mass, in turn becoming a risk factor for COPD patients' mortality. In their review regarding "Sarcopenia and frailty in chronic respiratory disease", Bone and co. (12) declare the association between frailty and poor outcomes amongst COPD patients. Maddocks and co. (13) found that frailty affect 25% of all COPD patients and that it is a significant factor for pulmonary rehabilitation failure. Nevertheless, they state that pulmonary rehabilitation programs are beneficial for frail, COPD patients, potentially reversing frailty characteristics even with a short-term rehabilitation program.

Low ALT activity in the peripheral blood is associated with low, total-body, muscle mass. This is specifically accurate when there is no spillage of ALT from hepatocytes to the peripheral blood, such as in cases of hepatitis. Therefore, in the current study, as done in previous studies, patients with higher than normal ALT values were excluded from analysis. Previous studies have demonstrated a significant correlation between ALT values and muscle mass, as demonstrated by computed tomography measurements (14) and between low ALT and frailty, as appreciated by the FRAIL questionnaire (15). Other studies have showed that low ALT levels are associated with long term all-cause mortality in the elderly population (16-19). Sarcopenia and the resultant frailty, represented by low activity of the enzyme ALT (SGPT) in the peripheral blood, were shown to be associated with shortened survival and other poor clinical outcomes, in various patients' populations and clinical
scenarios. It is postulated that this association rise from the fact that low ALT levels are the result of sarcopenia and the resultant frailty is the cause for shortening of life span in low-ALT populations (20–23).

However, there are no previous studies that examined the relationship between low ALT values and mortality amongst hospitalized patients with COPD exacerbation. The aim of the current study was to assess the association between ALT and clinical outcomes.

**Patients And Methods**

**Patient selection**

We executed a historic, prospective cohort study of COPD patients hospitalized to a single department of internal medicine, due to COPD exacerbation as their main diagnosis. The inclusion criteria were: a. age over 18 years, b. diagnosis of COPD exacerbation (ICD code 496) on discharge, c. available ALT blood levels, within the normal limits (lower than 40 IU/L) during the 3 months prior to admission. After study approval by an institutional ethics review board, we excluded patients with ALT levels greater than 40 IU/L, supposed to have hepatitis of any cause. We extracted patients' details from the computerized records, including epidemiologic characteristics, background diagnoses, long-term medications, laboratory parameters, short- and long-term clinical outcomes. The Norton scale, a score that is used by nurses around the world since the early 1960s to assess the risk of pressure ulcers upon admission and during hospitalization, was extracted too from the medical record. It includes five domains, each is a fundamental aspect of health in the elderly: physical condition, mental condition, activity, mobility, and incontinence (24).

**Statistical methods**

In order to assess the association between ALT levels and dichotomous variables we calculated the sample size, as appropriate for medium strength associations. In order to determine such association, we needed a sample size greater than 192 patients (for 1% significance and 80% power). The cohort size was determined using G Power software (25).

We assessed the distribution of continuous variables using histograms and Q-Q plots. We described continuous variables with normal distribution by means and standard deviations. Continuous variables
that did not have normal distribution were described using median and IQR (Inter-quartile range). We described categorical variables using frequency and percentages. We assessed the association of clinical outcomes with continuous variables using t-tests or Man-Whitney tests. We assessed the association of categorical variables with clinical outcomes using the chi-square tests or the exact fisher's test. We used logistic regression to assess the association between ALT values while correction of possible confounders. This was a two-block regression: the first block included ALT values and the second block included possible confounders, selected by using the forward stepwise methods and the Wald test. Statistical analysis was done using the SPSS software (IBM Corp., NY USA). All statistical tests were two-sided. We considered as significant only p values lower than 0.05.

Results
We included in this study 232 consecutive COPD patients, hospitalized due to COPD exacerbation in one internal-medicine department in a large, tertiary hospital, over a period of 38 months – from January 2015 to February 2018. After approval by an IRB, we extracted patients’ data from their computerized medical records. The mean age was 76.06 ± 10.7 years, median Norton score was 15.7 (IQR 13-19), median ALT level was 16.5 IU/L (IQR 11-20), median creatinine concentration was 1.15 mg/dL (IQR 0.74-1.35), and the mean albumin concentration was 3.6 ± 0.47 g/dL. Within our cohort, 74.6% had cardio-vascular diseases, 59.9% had metabolic diseases, 35.3% had diabetes, 25.4% had neurological diseases, and 24.1% suffered from hematological or hemato-oncological diseases. Regarding background medical treatments, 19.4% were treated by systemic steroids, 32.8% took anti-diabetic medications, and 84.1% had cardiovascular medications, 26.3% treated by anticoagulants and 67.7% were using inhalers regularly. Patients' characteristics, according to their baseline ALT values (lower quartile (< 11 IU/L) vs. upper three quartiles (11 IU/L < ALT < 40 IU/L)), are described in table 1. The median time of follow-up was 34.9 months (IQR 23.13 – 41.73). During this period 104 (44.8%) patients died. Figure 1 describe the flow of patients from recruitment to analysis and table 2 describe patient characteristics found to be associated with increased risk for mortality amongst our study cohort.

Table 01. Patients' characteristics according to baseline ALT levels
### Patients' demographics

|                      | ALT < 11 IU/L | 11 IU/L ≤ ALT ≤ 40 IU/L | P value |
|----------------------|--------------|--------------------------|---------|
| Age (years ± SD)     | 78.8 ± 9     | 74.8 ± 11.2              | 0.008   |
| Gender – males (n (%)) | 39 (54.9)    | 77 (47.8)                | 0.32    |
| Norton score (number, IQR) | 14.93 (13-17) | 16.06 (13.5-19)         | 0.002   |

### Background diagnoses (groups)

|                      | Alive | Dead | Hazard ratio (95% CI) | P value |
|----------------------|-------|------|-----------------------|---------|
| Cancer (n (%))       | 20 (28.2) | 36 (22.4) | 1.06 (1.04-1.08)     | < 0.001 |
| Dementia (n (%))     | 3 (4.2)   | 7 (4.3)  | NS                    |         |
| Diabetes (n (%))     | 33 (46.5) | 49 (30)  | 0.018                 |         |
| Cardiovascular (n (%)) | 54 (76.1) | 119 (73.9) | 0.73               |         |
| Metabolic (n (%))    | 47 (66.2) | 92 (57.1) | 0.19                 |         |
| Neurologic (n (%))   | 17 (23.9) | 42 (26.1) | 0.73                 |         |
| Endocrine (n (%))    | 12 (16.9) | 21 (13.0) | 0.49                 |         |

### Medications (groups)

|                      | Alive | Dead | Hazard ratio (95% CI) | P value |
|----------------------|-------|------|-----------------------|---------|
| Steroids (n (%))     | 17 (23.9) | 28 (17.4) | 2.06 (1.43-2.98)     | 0.007   |
| Anticoagulation (n (%)) | 27 (38)   | 34 (21.1) | 1.57 (1.31-2.57)     | < 0.001 |
| Inhalers/Inhalation (n (%)) | 46 (64.8) | 111 (68.9) | 1.86 (1.09-4.0)     | 0.042   |
| Anti-diabetic (n (%)) | 28 (39.4) | 48 (29.8)  | 0.37                 |         |
| Cardiovascular (n (%)) | 62 (87.3) | 133 (82.6) | 0.007               |         |
| Metabolic (n (%))    | 17 (23.9) | 33 (20.5)  | 0.56                 |         |
| Neurologic (n (%))   | 33 (46.5) | 62 (36.5)  | 0.25                 |         |

### Laboratory parameters

|                      | Alive | Dead | Hazard ratio (95% CI) | P value |
|----------------------|-------|------|-----------------------|---------|
| Albumin (g/dL ± SD)  | 3.4 ± 0.45 | 3.7 ± 0.45 | 1.06 (1.04-1.08)     | < 0.001 |
| Creatinine (mg/dL, (IQR)) | 1.32 (0.93-1.53) | 1.07 (0.68-1.29) | 0.007               |         |

### Clinical outcomes

|                      | Alive | Dead | Hazard ratio (95% CI) | P value |
|----------------------|-------|------|-----------------------|---------|
| Mortality (n (%))    | 49 (69.0) | 55 (34.2)  | 1.08 (1.05-1.11)     | < 0.001 |
| Survival time – median (months) | 18.5 | Median not reached |            |         |

P value using T-test analysis.

---

**Table 02. Patients' characteristics according to survival – univariate analysis.**

| Patients' characteristics | Alive | Dead | Hazard ratio (95% CI) | P value |
|---------------------------|-------|------|-----------------------|---------|
| Age (years ± SD)          | 72.89 ± 10.8 | 79.96 ± 9.2 | 1.06 (1.04-1.08)     | < 0.001 |
| Norton score (number, (IQR)) | 16.84 (15-19) | 14.33 (11.25-17) | 0.007               |         |
| Albumin (mg/dL ± SD)      | 3.69 ± 0.47 | 3.48 ± 0.45 | 2.06 (1.43-2.98)     | < 0.001 |
| Creatinine (mg/dL, (IQR)) | 1.03 (0.69-1.21) | 1.29 (0.84-1.62) | 0.007               |         |
| ALT (IU/L, IQR)           | 18.71 (13-23.75) | 13.77 (9-17) | 1.08 (1.05-1.11)     | < 0.001 |
| Cardiovascular disease (n (%)) | 89 (69.5) | 84 (80.8)  | 1.8 (1.1-2.93)       | 0       |
| Cardiovascular medications (n (%)) | 101 (78.9) | 94 (90.4)  | 2.09 (1.09-4.0)      | 0       |
| Neurologic medications (n (%)) | 41 (32.0) | 54 (51.9)  | 1.94 (1.31-2.68)     | 0       |
| Anticoagulation medications (n (%)) | 29 (18.8) | 37 (35.6)  | 1.73 (1.15-2.57)     | 0       |

P value using Chi-square analysis.
We divided all patients to quartiles according to their blood ALT levels (after exclusion of cases considered to have hepatitis (ALT > 40 IU)). The risk of long-term mortality increased, in a statistically significant manner, amongst patients with low ALT values: the median survival for patients with ALT < 11 IU was 18.5 months only while the median survival for the rest of the study group was not reached. For ALT < 11IU; 12-16IU; 17-20IU and >21IU the mortality rates were 69%; 40.9%; 36.3% and 25% respectively (p < 0.001 for comparison of lower quartile with upper three quartiles; figure 2).

The crude hazard ratio for mortality amongst patients with ALT levels lower than 11IU was 2.37 (95% CI; 1.6 – 3.5). This increased risk of mortality remained significant after controlling for age, weight, Norton score, creatinine, albumin concentration and cardiovascular diseases (HR = 1.83; 95% CI 1.08 – 3.1, p = 0.025). Table 3 describe the multivariate logistic regression for mortality in our study cohort.

**Table 03. Multivariate logistic regression for mortality in our study cohort.**

| Patients' characteristics                      | Hazard ratio (95% CI) | P value |
|-----------------------------------------------|-----------------------|---------|
| Lower quartile of ALT                         | 1.83 (1.08-3.1)       | 0.025   |
| Age                                           | 1.02 (0.99-1.05)      | 0.110   |
| Weight                                        | 0.98 (0.97-0.99)      | 0.02    |
| Low Norton score                              | 1.09 (1.02-1.17)      | 0.016   |
| High creatinine value                         | 1.79 (1.14-2.81)      | 0.011   |
| Low albumin concentration                     | 1.34 (0.85-2.42)      | 0.178   |
| Cardiovascular disease                        | 1.56 (0.83-2.94)      | 0.167   |

P value using Chi-square analysis

**Discussion**

As stated earlier, ALT is a biomarker for sarcopenia and frailty (14,15,23). In our study, we have showed that low ALT values, are associated with poor long-term survival amongst patients hospitalized due to COPD exacerbation. Of note, our results remained significant after controlling for parameters associated with frailty, i.e. Norton scale, albumin, etc.

Appreciation of sarcopenia and frailty enables a summation of patients' characteristics which are associated with his or her risk for subsequent morbidity and mortality. Addressing sarcopenia and frailty in quantitative measures should, therefore, better the prognostication process for many patients' populations. COPD patients should not be an outlier for the aforementioned declaration: these patients should be routinely evaluated for sarcopenia and frailty, and treatment strategies must
take into account these patient's characteristics.

Current literature promotes personalized medicine. However, most cases of personalized medicine are actually dealing with precise medicine: diagnostic approaches become more focused on disease and pathology rather than on the person / patient as a whole. We believe that thorough evaluation of sarcopenia and frailty should be considered as true personalized medicine.

In the current study we show that similarly to other patients' groups, COPD patients can also be classified as sarcopenic and frail, according to their baseline ALT values. ALT measurements are a part of routine blood tests and are available worldwide for any hospitalized patient. Acknowledgment of low ALT values during COPD exacerbation could aid the attending physician in taking better clinical / therapeutic decisions (duration and route of administration of steroids, duration and type of antibiotics, promoting physiotherapy sessions and rehabilitation programs prior to patient's discharge to the community etc.).

ALT measurement should not replace other, well established methods for sarcopenia and frailty appreciation. Nevertheless, most such evaluation tools were developed and are being used in the realm of geriatric medicine. The results of this study are applicable to the general population of COPD patients admitted to internal-medicine departments. For these reasons, we suggest that ALT values would be flagged, and diagnoses of sarcopenia and frailty should be highlighted in the discharge documents of COPD patients.

Limitations
In the study we performed a retrospective analysis and therefore, not all confounding parameters could be addressed. Moreover, while demonstrating significant statistical associations between ALT and mortality, causality could not be inferred. We performed the study on patients admitted to a single internal medicine department, that might not correlate perfectly to all COPD patients that are admitted to hospitals nationally.

Conclusion
Low ALT values are an independent marker for shortened survival of COPD patients after being hospitalized due to COPD exacerbation. Being a marker for sarcopenia and frailty, low ALT values in
these patients should prompt more aggressive therapeutic efforts on behalf of the attending physician. Future, prospective, interventional studies should aim at evaluation of different therapies and rehabilitation programs, concentrated at the sarcopenic and frail COPD patients.

**List Of Abbreviations**

ALT; Alanine amino-transferase. SGPT; Serum glutamic pyruvic transaminase. COPD; Chronic, obstructive pulmonary disease. CI; Confidence interval. IU; International units. IQR; Inter-quartile range. Q-Q Plot; Quantile-quantile plot.

**Declarations**

**Ethics approval and consent to participate**

This study was initiated only after approval by the institutional review board at the Chaim Sheba medical center. Approval number 5779-18-SMC. Since this was a retrospective study, consent was not relevant.

**Consent to publish**

All authors gave their consent for publication of the completed manuscript.

**Availability of data and materials**

All data is available with the authors for further study questions.

**Competing interests**

All authors declare they have no competing interests regarding this study and manuscript.

**Funding**

No external funding was given to this study. No funding to report.

**Authors' contributions**

Study design and planning: LN; SM; TN; GG; LY; LE; BG; ZSG; BA; CD; AC; SG. Data collection: LN; SM; TN; GG; SG. Data analysis: LN; SM; TN; GG; LY; LE; BG; ZSG; BA; CD; AC; SG. Manuscript writing and proofs: LN; SM; TN; GG; LY; LE; BG; ZSG; BA; CD; AC; SG. All authors have read and approved the manuscript.

**Acknowledgements**

NA
Authors' information

Gad Segal, MD. Internal medicine T, Chaim Sheba medical center, Tel Hashomer, 2nd Sheba road, Ramat Gan. Israel. Gad.segal@sheba.health.gov.il. +972-52-6669580.

Limitations

This was a retrospective analysis and therefor, not all confounding parameters could be addressed.
We demonstrated statistical associations but causality could not be inferred. Also, this study was done in a single department and results might be changed with different patients' demographics.

Bibliography

1. Laribi S, Keijzers G, van Meer O, Klim S, Motiejunaite J, Kuan W Sen, et al. Epidemiology of patients presenting with dyspnea to emergency departments in Europe and the Asia-Pacific region. Eur J Emerg Med. 2018 Aug;1.

2. Brown H, Dodic S, Goh SS, Green C, Wang W, Kaul S, et al. Factors associated with hospital mortality in critically ill patients with exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2018 Aug;Volume 13:2361–6.

3. Barrecheguren M, González C, Miravitlles M. What have we learned from observational studies and clinical trials of mild to moderate COPD? Respir Res. 2018 Dec;19(1):177.

4. Ryrsø CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med. 2018 Dec;18(1):154.

5. Takechi Y. [Intervention for COPD Exacerbation - How To Prevent and Treat COPD Exacerbation ?]. Gan To Kagaku Ryoho. 2016 Dec;43(Suppl 1):61–3.

6. Sakamoto Y, Yamauchi Y, Yasunaga H, Takeshima H, Hasegawa W, Jo T, et al. Development of a nomogram for predicting in-hospital mortality of patients with exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon
7. Serra-Picamal X, Roman R, Escarrabill J, García-Altés A, Argimón JM, Soler N, et al. Hospitalizations due to exacerbations of COPD: A big data perspective. Respir Med. 2018 Jan;

8. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012 Nov;40(5):1115–22.

9. Swallow EB, Reyes D, Hopkinson NS, Man WD-C, Porcher R, Cetti EJ, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007 Feb;62(2):115–20.

10. Morley JE, Kim MJ, Haren MT, Kevorkian R, Banks WA. Frailty and the aging male. Aging Male. 2005 Jan;8(3-4):135–40.

11. Vellas B, Fielding R, Bhasin S, Cerreta F, Goodpaster B, Guralnik JM, et al. Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force. J frailty aging. 2016;5(4):194–200.

12. Bone AE, Hepgul N, Kon S, Maddocks M. Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis. 2017 Feb;14(1):85–99.

13. Maddocks M, Kon SSC, Canavan JL, Jones SE, Nolan CM, Labey A, et al. Physical frailty and pulmonary rehabilitation in COPD: a prospective cohort study. Thorax. 2016;71(11):988–95.

14. Portal D, Hofstetter L, Eshed I, Dan Lantsman C, Sella T, Urban D, et al. L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients. Cancer Manag Res. 2019 Apr;Volume 11:2579–88.

15. Irina G, Refaela C, Adi B, Avia D, Liron H, Chen A, et al. Low Blood ALT Activity and High FRAIL Questionnaire Scores Correlate with Increased Mortality and with Each
Other. A Prospective Study in the Internal Medicine Department. J Clin Med. 2018 Oct;7(11):386.

16. Elinav E, Ackerman Z, Maaravi Y, Ben-Dov IZ, Ein-Mor E, Stessman J. Low alanine aminotransferase activity in older people is associated with greater long-term mortality. J Am Geriatr Soc. 2006 Nov;54(11):1719–24.

17. Koehler EM, Sanna D, Hansen BE, van Rooij FJ, Heeringa J, Hofman A, et al. Serum liver enzymes are associated with all-cause mortality in an elderly population. Liver Int. 2014 Feb;34(2):296–304.

18. Le Couteur DG, Blyth FM, Creasey HM, Handelsman DJ, Naganathan V, Sambrook PN, et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol A Biol Sci Med Sci. 2010 Jul;65(7):712–7.

19. Vespasiani-Gentilucci U, De Vincentis A, Ferrucci L, Bandinelli S, Antonelli Incalzi R, Picardi A. Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival. J Gerontol A Biol Sci Med Sci. 2018 Jun;73(7):925–30.

20. Ramati E, Israel A, Tal Kessler, Petz-Sinuani N, Sela B-A, Idan Goren, et al. [Low ALT activity amongst patients hospitalized in internal medicine wards is a widespread phenomenon associated with low vitamin B6 levels in their blood]. Harefuah. 2015 Feb;154(2):89-93, 137.

21. Ramaty E, Maor E, Peltz-Sinvani N, Brom A, Grinfeld A, Kivity S, et al. Low ALT blood levels predict long-term all-cause mortality among adults. A historical prospective cohort study. Eur J Intern Med. 2014 Dec;25(10):919-21.

22. Peltz-Sinvani N, Klempfner R, Ramaty E, Sela BA, Goldenberg I, Segal G. Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients. J Gen Intern Med. 2016;31(2):209-14.
Figures

Figure 1

Consort diagram of patients' flow in the current study.
Figure 2

Survival (months) of COPD patients according to baseline ALT values